The Emerging Use of Technology for the Treatment of Depression and Other Neuropsychiatric Disorders
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background: Our objective is to review emerging technologies intended for the treatment of depression and other neuropsychiatric disorders. Methods: These technologies include repetitive transcranial magnetic stimulation (rTMS), magnetic seizure therapy (MST), vagus nerve stimulation (VNS), deep brain stimulation (DBS), cortical brain stimulation (CBS), and quantitative electroencephalography (QEEG). Results: The rationale for these technologies, their mechanisms of action, and how they are used in clinical practice are described. rTMS and VNS are effective for treatment-resistant depression. DBS is effective for resistant obsessive-compulsive disorder. QEEG can help predict a patient's response to an antidepressant. All of these technologies continue to be investigated in treatment studies. Conclusions: As these and other emerging technologies for depression and other neuropsychiatric disorders are development and applied, psychiatrists should understand the rationale for these modalities, how they work, and how they can be used in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Mayberg, H. S. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.193 · Cited by 1,166
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Goldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.34 · Cited by 1,068
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic
Ressler, K. J., & Mayberg, H. S. (2007) · Nature Neuroscience · doi:10.1038/nn1944 · Cited by 1,007
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Cited by
Howland, R. H. (2014) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-014-0010-5 · Cited by 405
“Small open-label studies and case series reports have described the use of VNS for rapid cycling bipolar disorder, treatment-resistant anxiety disorders, Alzheimer’s disease, chronic refractory headaches, and obesity, although none of these uses has been given FDA approval [9].”
Self-citationBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Kraus, T., Kiess, O., Hösl, K., Terekhin, P., Kornhuber, J., & Forster, C. (2013) · Brain Stimulation · doi:10.1016/j.brs.2013.01.011 · Cited by 301
The Economic Burden of Treatment-Resistant Depression
Olchanski, N., McInnis Myers, M., Halseth, M., Cyr, P. L., Bockstedt, L., Goss, T. F., & Howland, R. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.001 · Cited by 146
Self-citation
Metadata
- Authors
- Howland, R. H., Shutt, L. S., Berman, S. R., Spotts, C. R., & Denko, T.
- Venue
- Annals of Clinical Psychiatry
- Publisher
- SAGE Publications
- Published
- 2011-02
- Volume
- 23
- Issue
- 1
- Pages
- 48-62
- ISSN
- 1040-1237 (ISSN-L)
- 1547-3325
- OpenAlex
- W11672392
- Cited by
- 46
- References
- 24
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Emerging Use of Technology for the Treatment of Depression and Other Neuropsychiatric Disorders. https://app.cochat.ai/papers/10.1177/104012371102300108
- The paper
- Howland, R. H., Shutt, L. S., Berman, S. R., Spotts, C. R., & Denko, T. (2011). The Emerging Use of Technology for the Treatment of Depression and Other Neuropsychiatric Disorders. Annals of Clinical Psychiatry. https://doi.org/10.1177/104012371102300108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.